Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share. The trade was executed under a Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. After this transaction, he holds 56,521 shares, including 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,722 shares of common stock at an average price of $156.1192 per share. The sale was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs, and Jack now holds 123,269 shares, including 51,388 RSUs and 479 shares acquired through the employee stock purchase plan.
Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share. The footnotes state this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter intended to satisfy tax withholding obligations related to vested restricted stock units. After the sale, Kelsey directly owned 291,876 shares, which the disclosure notes includes 76,251 RSUs and 653 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a mix of option exercises and stock sales. On June 15 and June 17, 2026, she exercised stock options covering a total of 90,000 shares of common stock at exercise prices of $26.50, $29.80, and $40.74 per share.
Across June 15 and June 17, 2026 and June 16, 2025, she sold 93,575 shares of common stock in open-market transactions at weighted average prices around $156–$160 per share. Footnotes state that the 2026 transactions were effected under a Rule 10b5-1 trading plan and that an earlier Rule 10b5-1 instruction letter addressed tax withholding obligations on RSU vesting.
After these transactions, Horn continues to hold a significant direct equity position, including restricted stock units noted in the footnotes.
Revolution Medicines insider Mark A. Goldsmith reported sales of Common Stock via Form 144. The filing lists a transfer of 12,871 shares on 03/17/2026 for $1,280,412.23 and a transfer of 120,000 shares on 04/15/2026 for $18,010,488.00. The filing also shows restricted stock unit grants of 3,488, 3,018 and 3,266 awarded on 03/01/2023, 03/01/2024 and 03/01/2025, respectively.
Revolution Medicines, Inc. sale notice by affiliate Jeff Cislini for Common Stock under Rule 144. The filing lists two reported dispositions: 1,795 shares sold on 03/17/2026 for $178,567.32 and 1,163 shares sold on 03/19/2026 for $113,322.72. The form also lists several restricted stock unit grants with grant dates and share counts as background.
Revolution Medicines reported the sale of 2,753 shares of Common Stock by a selling party on 03/17/2026, with proceeds shown as $273,869.54.
The filing also lists prior restricted stock unit grants of 318, 846, 840, and 649 shares dated 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, respectively.
Revolution Medicines (RVMD) Rule 144 sale notice reporting insider dispositions. The filing lists recent open‑market sales of Common Stock by Anthony Mancini: 37,450 shares on 03/25/2026, 3,120 shares on 04/27/2026, and 3,121 shares on 05/26/2026, each with an associated dollar amount. The filing also shows a restricted stock unit grant dated 04/01/2025 for 4,211 shares tied to services rendered. Shares outstanding are listed as 212,596,462 as of 06/15/2026 in the provided excerpt.
Stephen Michael Kelsey filed a Form 144 notice to sell 4,071 shares of Common Stock of Revolution Medicines. The filing lists restricted stock unit grants dated 03/01/2023, 03/01/2024, and 03/01/2025 totaling 4,071 units. It also reports that 4,302 shares were sold on 03/17/2026 for $427,964.68.
Revolution Medicines (RVMD) submitted a Form 144 notice reporting proposed sales of Common Stock by an insider. The filing lists two dispositions by Margaret A. Horn: 4,583 shares on 03/17/2026 (proceeds $455,918.67) and 10,000 shares on 06/11/2026 (proceeds $1,480,140.00). The filing also lists restricted stock unit grants of 1,272, 1,304, and 910 shares dated 03/01/2023, 03/01/2024, and 03/01/2025 respectively. Shares outstanding are shown as 212,596,462 as of 06/15/2026.